Cargando…

Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity

BACKGROUND: Dipeptidyl peptidase 4 (DPP4) and angiotensin-converting enzyme (ACE) are important target enzymes in glycemic control and renovascular protection. Here, we studied the effect of NWT-03, an egg protein hydrolysate with DPP4- and ACE-inhibitory activity, on renovascular damage in Zucker d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yumei, Landheer, Sjoerd, van Gilst, Wiek H., van Amerongen, Aart, Hammes, Hans-Peter, Henning, Robert H., Deelman, Leo E., Buikema, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468629/
https://www.ncbi.nlm.nih.gov/pubmed/23071636
http://dx.doi.org/10.1371/journal.pone.0046781
_version_ 1782245975505502208
author Wang, Yumei
Landheer, Sjoerd
van Gilst, Wiek H.
van Amerongen, Aart
Hammes, Hans-Peter
Henning, Robert H.
Deelman, Leo E.
Buikema, Hendrik
author_facet Wang, Yumei
Landheer, Sjoerd
van Gilst, Wiek H.
van Amerongen, Aart
Hammes, Hans-Peter
Henning, Robert H.
Deelman, Leo E.
Buikema, Hendrik
author_sort Wang, Yumei
collection PubMed
description BACKGROUND: Dipeptidyl peptidase 4 (DPP4) and angiotensin-converting enzyme (ACE) are important target enzymes in glycemic control and renovascular protection. Here, we studied the effect of NWT-03, an egg protein hydrolysate with DPP4- and ACE-inhibitory activity, on renovascular damage in Zucker diabetic fatty (ZDF) rats. Comparisons were made to rats treated with vildagliptin (VIL), included as a positive control for the effect of DPP4 inhibition. METHODS: ZDF rats received NWT-03 (1 g/kg/day) or VIL (3 mg/kg/day) from 10 to 25 weeks of age. Metabolic and renal functions were assessed; the kidney was removed for histological analysis of glomerulosclerosis and expression of pro-inflammatory/fibrotic markers (RT-PCR and Western blotting); and the aorta was removed for studies of endothelium-dependent relaxation (EDR). FINDINGS: Hyperinsulinemic ZDF rats typically developed signs of type-2 diabetes and renovascular damage, as evidenced by albuminuria, glomerulosclerosis, and impaired EDR. Neither NWT-03 nor VIL improved metabolic parameters; for VIL, this was despite a 5-fold increase in glucagon-like peptide (GLP)-1 levels. NWT-03 and VIL both reduced renal interleukin (Il)-1β/Il-13 mRNA expression and glomerulosclerosis. However, only NWT-03 additionally decreased renal tumor necrosis factor (TNF)-α mRNA and P22(phox) protein expression, reduced albuminuria, and restored aortic EDR. Indomethacin added to the organ bath instantly improved aortic EDR, indicating a role for cyclooxygenase (COX)-derived contractile prostanoids in opposing relaxation in ZDF rats. This indomethacin effect was reduced by NWT-03, but not by VIL, and coincided with decreased renal COX-1/2 protein expression. CONCLUSION AND INTERPRETATION: Long-term supplementation with the egg protein hydrolysate NWT-03 attenuated renovascular damage in this preclinical rat model of type 2 diabetes. A comparison to the DPP4-inhibitor VIL suggests that the effects of NWT-03 were related to both ACE- and DPP4-inhibitory properties. The development of protein hydrolysates with a multiple-targeting strategy may be of benefit to functional food formulations.
format Online
Article
Text
id pubmed-3468629
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34686292012-10-15 Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity Wang, Yumei Landheer, Sjoerd van Gilst, Wiek H. van Amerongen, Aart Hammes, Hans-Peter Henning, Robert H. Deelman, Leo E. Buikema, Hendrik PLoS One Research Article BACKGROUND: Dipeptidyl peptidase 4 (DPP4) and angiotensin-converting enzyme (ACE) are important target enzymes in glycemic control and renovascular protection. Here, we studied the effect of NWT-03, an egg protein hydrolysate with DPP4- and ACE-inhibitory activity, on renovascular damage in Zucker diabetic fatty (ZDF) rats. Comparisons were made to rats treated with vildagliptin (VIL), included as a positive control for the effect of DPP4 inhibition. METHODS: ZDF rats received NWT-03 (1 g/kg/day) or VIL (3 mg/kg/day) from 10 to 25 weeks of age. Metabolic and renal functions were assessed; the kidney was removed for histological analysis of glomerulosclerosis and expression of pro-inflammatory/fibrotic markers (RT-PCR and Western blotting); and the aorta was removed for studies of endothelium-dependent relaxation (EDR). FINDINGS: Hyperinsulinemic ZDF rats typically developed signs of type-2 diabetes and renovascular damage, as evidenced by albuminuria, glomerulosclerosis, and impaired EDR. Neither NWT-03 nor VIL improved metabolic parameters; for VIL, this was despite a 5-fold increase in glucagon-like peptide (GLP)-1 levels. NWT-03 and VIL both reduced renal interleukin (Il)-1β/Il-13 mRNA expression and glomerulosclerosis. However, only NWT-03 additionally decreased renal tumor necrosis factor (TNF)-α mRNA and P22(phox) protein expression, reduced albuminuria, and restored aortic EDR. Indomethacin added to the organ bath instantly improved aortic EDR, indicating a role for cyclooxygenase (COX)-derived contractile prostanoids in opposing relaxation in ZDF rats. This indomethacin effect was reduced by NWT-03, but not by VIL, and coincided with decreased renal COX-1/2 protein expression. CONCLUSION AND INTERPRETATION: Long-term supplementation with the egg protein hydrolysate NWT-03 attenuated renovascular damage in this preclinical rat model of type 2 diabetes. A comparison to the DPP4-inhibitor VIL suggests that the effects of NWT-03 were related to both ACE- and DPP4-inhibitory properties. The development of protein hydrolysates with a multiple-targeting strategy may be of benefit to functional food formulations. Public Library of Science 2012-10-10 /pmc/articles/PMC3468629/ /pubmed/23071636 http://dx.doi.org/10.1371/journal.pone.0046781 Text en © 2012 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Wang, Yumei
Landheer, Sjoerd
van Gilst, Wiek H.
van Amerongen, Aart
Hammes, Hans-Peter
Henning, Robert H.
Deelman, Leo E.
Buikema, Hendrik
Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity
title Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity
title_full Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity
title_fullStr Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity
title_full_unstemmed Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity
title_short Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity
title_sort attenuation of renovascular damage in zucker diabetic fatty rat by nwt-03, an egg protein hydrolysate with ace- and dpp4-inhibitory activity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468629/
https://www.ncbi.nlm.nih.gov/pubmed/23071636
http://dx.doi.org/10.1371/journal.pone.0046781
work_keys_str_mv AT wangyumei attenuationofrenovasculardamageinzuckerdiabeticfattyratbynwt03aneggproteinhydrolysatewithaceanddpp4inhibitoryactivity
AT landheersjoerd attenuationofrenovasculardamageinzuckerdiabeticfattyratbynwt03aneggproteinhydrolysatewithaceanddpp4inhibitoryactivity
AT vangilstwiekh attenuationofrenovasculardamageinzuckerdiabeticfattyratbynwt03aneggproteinhydrolysatewithaceanddpp4inhibitoryactivity
AT vanamerongenaart attenuationofrenovasculardamageinzuckerdiabeticfattyratbynwt03aneggproteinhydrolysatewithaceanddpp4inhibitoryactivity
AT hammeshanspeter attenuationofrenovasculardamageinzuckerdiabeticfattyratbynwt03aneggproteinhydrolysatewithaceanddpp4inhibitoryactivity
AT henningroberth attenuationofrenovasculardamageinzuckerdiabeticfattyratbynwt03aneggproteinhydrolysatewithaceanddpp4inhibitoryactivity
AT deelmanleoe attenuationofrenovasculardamageinzuckerdiabeticfattyratbynwt03aneggproteinhydrolysatewithaceanddpp4inhibitoryactivity
AT buikemahendrik attenuationofrenovasculardamageinzuckerdiabeticfattyratbynwt03aneggproteinhydrolysatewithaceanddpp4inhibitoryactivity